- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Timothy Yap: Rucaparib/Sacituzumab Govitecan Combo Effective Against Triple-Negative Disease
A novel combination shows promise against advanced solid tumors, including triple-negative breast cancer, noted Timothy A. Yap, MBBS, PhD, FRCP, medical director of the Institute for Applied Cancer Science at MD Anderson Cancer Center.
Advanced solid tumors responded favorably to the combination of rucaparib plus sacituzumab govitecan, according to results of the phase 1B SEASTAR study presented at this year’s virtual European Society for Medical Oncology (ESMO) meeting by Timothy A. Yap, MBBS, PhD, FRCP, medical director, Institute for Applied Cancer Science; associate professor, Department of Investigational Cancer Therapeutics (Phase I Program), Department of Thoracic/Head and Neck Medical Oncology; and associate director of Translational Research, Khalifa Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center.
Transcript
Tell us about the SEASTAR study and the data you presented at ESMO on triple-negative breast cancer.
The arm of the phase 1B/phase 2 SEASTAR study that I presented at ESMO evaluated a novel combination of the PARP inhibitor rucaparib with sacituzumab govitecan, which is a TROP2-directed antibody conjugated to a topoisomerase 1 inhibitor, SN-38, that we conducted in patients with advanced solid tumors. This is the first presentation of these data of this novel combination.
And so in this trial, patients with metastatic triple-negative breast cancer were indeed included in this phase 1B part of the study, as were patients with other advanced or metastatic solid tumors, such as platinum-resistant ovarian cancer and also urothelial cancers. This first presentation of data from the phase 1B portion of the SEASTAR study showed very encouraging signals of antitumor activity.
The antitumor activity was observed with the combination in patients with different solid tumors, including patients with prior PARP inhibitor exposure and also those without a deleterious homologous recombination repair gene mutation. Despite early toxicities, including dose limiting and neutropenia in 2 out of 3 patients at the higher dose level, all 6 patients continued treatment for at least 12 weeks, with treatment-related toxicities effectively managed with dose modifications and/or growth factor support.
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Dr Michael Farwell on FDG PET/CT Imaging to Predict Immunotherapy Response in Advanced Melanoma
April 15th 2024Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT imaging to detect metabolic tumor changes in skin cancer.
Read More
